TherageniX is an early-stage biotechnology company with a focus on tissue regeneration through gene therapy. The company's mission is to enhance autologous bone grafts using proprietary technology to improve regenerative capacity and reduce donor site trauma. Given that approximately 4 million grafting procedures are conducted annually worldwide and with a significant number failing due to rejection, infection, or inadequate functionality, TherageniX addresses a critical need in the global bone grafts and substitutes market.
Founded in 2022, TherageniX was built by NLC, the European healthtech venture builder, and licensed technology from Dr. James Dixon's group at the University of Nottingham with the support of Nottingham Technology Ventures Ltd. The company recently secured a significant £995.00K grant investment from Innovate UK on 31 August 2023, signifying confidence in its innovative approach to tissue regeneration through gene therapy.
With its innovative approach and strategic partnerships, TherageniX is positioned to make a significant impact in the biotechnology and healthcare industries, addressing the unmet needs in bone grafting procedures and paving the way for more effective tissue regeneration treatments.
